Search Results

Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

had no history of heart attack or stroke, an LDL-C ≥ 90 mg/dL, or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 120 mg/dL, or apolipoprotein B ≥ 80 mg/dL; and treated with highest tolerated dose of statin and/or ezetimibe. The median baseline LDL-C was 122 mg/dL (IQR, 104-149 mg/dL) on local lab

More news about: Amgen

Jun 07, 2026, 16:45 ET Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes

myocardial infarction or stroke with an elevated LDL-C ≥90 mg/dL while on an optimized lipid-lowering therapy. Evolocumab is an injection that helps the body remove bad cholesterol from the blood. Researchers randomized patients with high "bad" cholesterol (LDL-C >90mg/dL) and atherosclerosis or high-risk

More news about: American Diabetes Association

Jun 07, 2026, 16:42 ET Quantinuum anuncia el cierre de su oferta pública inicial ampliada

oferta está disponible únicamente a través de un Departamento de Prospectos. Se pueden obtener copias del prospecto mediante: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 o por correo electrónico a

More news about: Quantinuum

Jun 07, 2026, 16:39 ET Quantinuum anuncia o fechamento de oferta pública inicial ampliada

www.sec.gov. A oferta está disponível apenas por meio de um prospecto. Cópias do prospecto podem ser obtidas em: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 ou por e-mail em [email protected]

More news about: Quantinuum

Jun 06, 2026, 20:27 ET 전 세계 출산 지연 및 난임 증가로 국경 간 난임 치료 수요 확대

multimedia:https://www.prnewswire.com/kr/news-releases/uC804u002DuC138uACC4u002DuCD9CuC0B0u002DuC9C0uC5F0u002DuBC0Fu002DuB09CuC784u002DuC99DuAC00uB85Cu002DuAD6DuACBDu002DuAC04u002DuB09CuC784u002D-302793336.htmlSOURCE

More news about: TFC Taipei Fertility Center

Jun 06, 2026, 16:20 ET Philippine Airlines to Join oneworld Alliance

"This is a defining and transformative moment for Philippine Airlines," said PAL Holdings, Inc. President Lucio C. Tan III. "Becoming a member of the oneworld Alliance and strengthening Southeast Asia's representation within the group significantly brings the

More news about: oneworld Management Company, Inc

Jun 06, 2026, 16:13 ET Philippine Airlines to Join oneworld Alliance

"This is a defining and transformative moment for Philippine Airlines," said PAL Holdings, Inc. President Lucio C. Tan III. "Becoming a member of the oneworld Alliance and strengthening Southeast Asia's representation within the group significantly brings the

More news about: oneworld Management Company, Inc

Jun 06, 2026, 14:45 ET 82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

minority participants; A1C 7.1% to 14.9%). The trial evaluated the impact of CGM on blood glucose management and A1C levels (a way to understand blood glucose levels over the past two or three months) over 26 weeks. At baseline, mean A1C was 8.8%, with 31% of participants having an A1C ≥9%. In addition, 37%

More news about: American Diabetes Association

Jun 06, 2026, 14:30 ET Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

placebo.Findings demonstrated that retatrutide achieved strong glucose control, significant improvements in A1C, and substantial weight reduction. Participants experienced up to a 2% reduction in A1C and a 16.8% (average loss of 36.6 lbs.) reduction in body weight. Retatrutide also showed improvements across

More news about: American Diabetes Association

Jun 06, 2026, 14:30 ET Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

diabetes, delivering significant A1C reduction along with substantial weight loss. For the primary endpoint, participants taking retatrutide achieved average A1C reductions of up to 2.0% from a baseline of 7.9%. Notably, up to 90% of participants taking retatrutide achieved an A1C below 7.0%, the American Diabetes

More news about: Eli Lilly and Company

Jun 06, 2026, 13:00 ET Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions

0.93)].2 Changes in biomarkers that reflect inflammation were also evaluated from baseline to week 104; there was a reduction in high sensitivity C-reactive protein (hsCRP) of 38.9% from baseline observed in patients taking semaglutide injection 2.4 mg, with no changes in blood eosinophil or neutrophil

More news about: NOVO NORDISK INC.

Jun 06, 2026, 11:57 ET /C O R R E C T I O N -- U.S. Postal Service/

More news about: U.S. Postal Service

Jun 06, 2026, 10:47 ET Quantinuum、増額された新規株式公開の完了を発表

Commission（「SEC」）により発効が宣言されました。本募集に関する目論見書（発行条件を記載したもの）はSECに提出されており、SECのウェブサイト（www.sec.gov）で閲覧可能です。本募集は、目論見書のみにより行われます。目論見書は下記から入手可能です。J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717、または電子メール：[email protected]および

More news about: Quantinuum

Jun 06, 2026, 10:42 ET Quantinuum annonce la clôture de son premier appel public à l'épargne élargi

L'offre n'est disponible que par l'intermédiaire d'un prospectus. Des copies du prospectus peuvent être obtenues auprès de : J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 ou par e-mail à [email protected]

More news about: Quantinuum

Jun 06, 2026, 10:15 ET Quantinum anuncia el cierre de su oferta pública inicial ampliada

www.sec.gov. La oferta se realiza disponible solo a través de un prospecto. Se pueden obtener copias del prospecto de: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, Nueva York 11717 o por correo electrónico a

More news about: Quantinuum

Jun 06, 2026, 10:12 ET 퀀티넘, 규모가 확대된 기업공개 완료 발표

www.sec.gov에서 확인할 수 있다. 이번 공모는 투자설명서를 통해서만 이루어진다. 투자설명서 사본은 J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 또는 이메일 [email protected]

More news about: Quantinuum

Jun 06, 2026, 10:06 ET Quantinuum gibt Abschluss des erweiterten Börsengangs bekannt

verfügbar. Das Angebot wird nur mittels eines Prospekts zur Verfügung gestellt. Exemplare des Prospekts sind erhältlich bei: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 oder per E-Mail an

More news about: Quantinuum

Jun 06, 2026, 09:07 ET コンピューテックス2026（Computex 2026）：AMZFAST、ゲーミングモニターの枠を超え、スマートディスプレイ、有機EL技術、400Hzのeスポーツ向け性能を展開

L DUAL Modeも含まれます。ゲーミング向け以外にも、AMZFASTはクリエイター向けおよび生産性向上用途のディスプレイを複数展示しました。AMZG34C85Lは、DCI-P3カバー率98%の34インチ5K2Kウルトラワイド仕様を採用しており、B27A2Uは、4K解像度、120HzのIPSパネル、DCI-P3色精度99%、90W USB-C充電を組み合わせ、プロフェッショナル用途のワークフローに対応します。フラッグシップモデルのAMZG49C7は、1台のシームレスなディスプレイで、QHDモニター2台分に相当する49インチ5K DQHDスーパーウルトラワイドの表示環境を実現し

More news about: AMZFAST

Jun 06, 2026, 09:07 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

semaglutide 2 mg compares with switching to tirzepatide and supports patient goals for HbA1c and weight loss. By one year, both groups were associated with similar proportions of patients achieving an HbA1c of <7%, and people on semaglutide 2 mg had a statistically significant higher

More news about: Novo Nordisk

Jun 06, 2026, 09:01 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

semaglutide 2 mg compares with switching to tirzepatide and supports patient goals for HbA1c and weight loss. By one year, both groups were associated with similar proportions of patients achieving an HbA1c of <7%, and people on semaglutide 2 mg had a statistically significant higher

More news about: Novo Nordisk

Jun 06, 2026, 06:56 ET XCMG 그룹과 ZF, 농업기계 합작사 설립

multimedia:https://www.prnewswire.com/kr/news-releases/u0078u0063u006Du0067u002DuADF8uB8F9uACFCu002Du007Au0066u002Cu002DuB18DuC5C5uAE30uACC4u002DuD569uC791uC0ACu002DuC124uB9BD-302793228.htmlSOURCE

More news about: XCMG Machinery

Jun 06, 2026, 06:46 ET '시진핑 영도하의 중국의 거버넌스' 제1권 러시아어판, 상트페테르부르크에서 출간

multimedia:https://www.prnewswire.com/kr/news-releases/u0027uC2DCuC9C4uD551u002DuC601uB3C4uD558uC758u002DuC911uAD6DuC758u002DuAC70uBC84uB10CuC2A4u0027u002DuC81Cu0031uAD8Cu002DuB7ECuC2DCuC544uC5B4-302793227.htmlSOURCE

More news about: Xinhua

Jun 05, 2026, 22:00 ET Roblox Investigation Initiated: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Roblox Corporation - RBLX

NEW YORK and NEW ORLEANS, June 5, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), is investigating claims on behalf of investors of

More news about: Kahn Swick & Foti, LLC

Jun 05, 2026, 22:00 ET Lockheed Martin Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lockheed Martin Corporation - LMT

NEW YORK and NEW ORLEANS, June 5, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of

More news about: Kahn Swick & Foti, LLC